CAR-T cell therapy is already a potent treatment for certain cancers. Now, a small study is showing early promise for ...

The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV treatment that pairs two drug classes in a single tablet. The approval gives ...

Three people were able to suppress the virus for months without their usual treatment regimen.

Merck has FDA approval for a new combination drug for HIV, giving patients a new treatment option and an alternative to a blockbuster Gilead Sciences pill that comes with tolerability and side effect ...

By Deena Beasley May 11 (Reuters) - Re-engineering an HIV patient's own immune cells to find and destroy the virus succeeded ...

Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety.

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...

A therapy originally developed for HIV now provides new options for patients with rare genetic disorders. It’s now possible to use these drugs to address DNA defects and enhance muscle function. This ...

Please provide your email address to receive an email when new articles are posted on . Previous studies have shown that DOR/ISL was noninferior to continuing current HIV therapies At 48 weeks, 91.8% ...

South Africa partners with Unitaid to produce generic lenacapavir by 2026. Discover how this HIV breakthrough improves access ...

Biktarvy continues to be a strong growth asset for Gilead, while Yeztugo’s launch rides an upward trajectory.